Our liposomal formulations not only offer greater stability and enhanced bioavailability but also scientifically superior performance
This chronic, systemic depletion allows environmental toxins and latent, dormant infections (such as EBV or human herpesviruses) to reactivate and accumulate, continuously driving immune dysfunction, mast cell activation syndrome (MCAS), and unrelenting fatigue
As with the Wegovy injection, effective contraception is required because semaglutide should not be used in pregnancy
Semaglutide Regulatory Status in Canada Health Canada Approval Status (Ozempic, Wegovy, Rybelsus, Generic) Semaglutide is the active ingredient in three Novo Nordisk products authorized for sale in Canada: Ozempic (authorized 2018 for type 2 diabetes, with an expanded indication in 2024 to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes), Rybelsus (oral semaglutide tablets authorized for type 2 diabetes), and Wegovy (authorized 2021 for chronic weight management, with an expanded indication in 2024 to reduce the risk of non-fatal myocardial infarction, and a Notice of Compliance with Conditions issued in December 2025 for non-cirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis)
